|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:ageRange
|
18 Years and older
|
|
gptkbp:allocates
|
Randomized
|
|
gptkbp:clinicalTrialPhase
|
Phase 2
|
|
gptkbp:clinicalTrialsGovURL
|
https://clinicaltrials.gov/ct2/show/NCT02366143
|
|
gptkbp:completedIn
|
October 2018
|
|
gptkbp:conditionStudied
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:enrollment
|
123
|
|
gptkbp:gender
|
All
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
NCT02366143
|
|
gptkbp:intervention
|
gptkb:Pembrolizumab
Chemotherapy
|
|
gptkbp:location
|
gptkb:Canada
gptkb:France
gptkb:United_States
|
|
gptkbp:mask
|
None (Open Label)
|
|
gptkbp:officialName
|
A Phase II Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy in First Line Metastatic Non-Small Cell Lung Cancer (NSCLC)
|
|
gptkbp:primaryCompletionDate
|
October 2018
|
|
gptkbp:result
|
gptkb:Objective_Response_Rate
|
|
gptkbp:secondaryOutcome
|
Overall Survival
Progression-Free Survival
|
|
gptkbp:sponsor
|
gptkb:Merck_Sharp_&_Dohme_LLC
|
|
gptkbp:startDate
|
February 2015
|
|
gptkbp:studyType
|
Interventional
|
|
gptkbp:bfsParent
|
gptkb:IMpower150
|
|
gptkbp:bfsLayer
|
7
|